Prostate

Guerbet: 2023 full-year results.

Retrieved on: 
수요일, 4월 10, 2024
CER, MRI, Guerbet, Growth, Medical imaging, Prostate, WCR, Software, IBM, Bank statement, IBM Watson, Iodine, Depreciation, NB, Liver, Artificial intelligence

The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.

Key Points: 
  • The Group’s operating income came to €38.7m in 2023, compared with a loss of €18.2m the previous year.
  • At 31 December 2023, Guerbet's net income stood at €22.2m, compared with a loss of €41.1m in 2022.
  • Free cash flow for full-year 2023 stood at -€65.4m, having entered positive territory in the second half at +€6.6m.
  • Financially, after comfortably achieving the business and profitability targets it had set for 2023, the Group is looking to 2024 with increased confidence.

EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Retrieved on: 
수요일, 4월 10, 2024
Certification, Radiation, Prostate cancer, Prostate, Seed, Eye, MDR, Neoplasm, Way, Brachytherapy, Medical device regulation, Health, Medical device

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

Key Points: 
  • Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
    The issuer is solely responsible for the content of this announcement.
  • This important milestone guarantees a high level of patient safety and the long-term availability of the seeds within the EU.
  • Prostate seeds have been manufactured and internationally marketed by Eckert & Ziegler since 1999 and contribute several million euros in annual sales to the Eckert & Ziegler Group's earnings.
  • This is not only a significant achievement for the distribution of our brachytherapy products, but for the entire Eckert & Ziegler Group," explained Katrin Antonenko, Managing Director of Eckert & Ziegler BEBIG GmbH.

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
화요일, 4월 9, 2024
TME, Toxicity, Metastasis, Enzyme, Survival, Cleavage, IL-2R, Brain, Patient, Tumor microenvironment, Mouse, Breast, Cancer, Prostate, Science, MDNA, AACR, TSX, Neoplasm, Metalloproteinase, Breast cancer, Poster, Medical imaging

TORONTO and HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data on MDNA113, the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) candidate, an IL-13R⍺2 (Interleukin-13 receptor alpha2) specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9th, 2024.

Key Points: 
  • Key findings presented at the conference include:
    When not activated, MDNA113 shows reduced IL-2R agonism with no change to PD-1/PDL-1 blockade activity.
  • MDNA113 selectively binds IL-13R⍺2 positive tumor cells in vitro, and durably accumulates (>7 days) in IL-13R⍺2 positive tumors in mice.
  • Single neoadjuvant treatment with MDNA113 in a highly invasive orthotopic 4T1.2 breast cancer model significantly increases survival by preventing metastasis.
  • It will be also available on the Scientific Presentations page of Medicenna’s website following the conclusion of the 2024 Annual Meeting of AACR.

Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
화요일, 4월 9, 2024
Curium, Civil service commission, Prostate cancer, Patient, PET, News, INN, Cancer, Prostate, European, European Commission, FDA, Nuclear medicine, Physician, PSMA, Food, Medical imaging

PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.

Key Points: 
  • PARIS, April 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in the Netherlands the first commercial dose of PYLCLARI® has been sold.
  • In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.
  • It is the #1 utilized PSMA PET agent in the U.S. market.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
화요일, 4월 9, 2024
Well, BRM, Acetyltransferase, Gene expression, Survival, NSCLC, PD, SMARCA2, Neoplasm, Megakaryocyte, Cancer, Prostate, Lung cancer, Protein, IND, EP300, AACR, ATPase, Therapy, BRG1, Safety, CBP, Lilly, Anemia, ID, Thrombocytopenia, Annual general meeting, Pharmaceutical industry

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Perma-Fix Successfully Completes Pilot Plant Testing and Unveils New Process for Destruction of PFAS “Forever Chemicals”

Retrieved on: 
수요일, 4월 3, 2024
AFFF, Pregnancy, Centofanti, Obesity, Pressure, PFAS, Incineration, Environment, Cancer, Water pollution, Puberty, Risk, Calcium fluoride, Research, History, PESI, Fertility, Prostate, Commercial, Human, Chemistry, Infection, Ecosystem, Water, Kidney, Patent, Biosolids, Government, Cosmetics

Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.

Key Points: 
  • Present disposal options for PFAS liquids include deep wells, incineration and landfills, all of which have serious environmental liability issues.
  • We expect that the Perma-Fix’s process will virtually eliminate PFAS compounds (minimum of 99.9999% destruction) and reduces the environmental liability associated with these materials.
  • Additionally, the process is designed to operate at a highly competitive price compared to traditional disposal options.
  • According to a recent article in Barron’s the estimated cleanup cost for PFAS compounds could exceed $200 billion.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
목요일, 3월 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
목요일, 3월 28, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, Cancer, Prostate, FLA, Urinary incontinence, Erectile dysfunction, CLS, FDA, Physician, Medical imaging

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Operating under CLS's Mobile Services Agreement, CLS will provide its FDA 510(k) cleared TRANBERG Laser, consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during procedures.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
화요일, 3월 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
화요일, 3월 26, 2024
Research, Consultant, Administration, Patient, Breast, Prostate, Insurance, IND, Data collection, Investment, Interim, Therapy, Research and development, FDA, NK, Pharmaceutical industry

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $1.36 million compared to $2.84 million for the same quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $1.81 million compared to $2.94 million for the same quarter in 2022.
  • Other income net of other expenses, for the fourth quarter ended December 31, 2023 was $0.21 million compared to $0.19 million for the same quarter ended December 31, 2022.
  • Net Loss: The Company reported a net loss of $2.96 million for the fourth quarter ended December 31, 2023 compared to a loss of $5.58 million for the same quarter in 2022.